Long-term efficacy of idebenone in DMD demonstrated in SYROS study

Results from the SYROS study demonstrate that long-term treatment with idebenone consistently reduced the rate of respiratory function loss in patients with Duchenne muscular dystrophy (DMD) for up to six years in a real-world setting. T

This long-term data further supports the potential for idebenone to modify the course of respiratory function decline and delay the time to clinically relevant milestones., says the drug’s developer, Swiss firm Santhera Pharmaceuticals (SIX: SANN), whose share rocketed 74.27% to 9.38 Swiss francs following the announcement.

Raxone/Catena (idebenone) has not received full regulatory approval, but has been made available there under an Expanded Access Program (EAP) in the USA, referred to as BreatheDMD, as well as similar schemes elsewhere.